You are here

Technology for bioactivity based discovery of novel cytokine receptor agonists

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM105306-01
Agency Tracking Number: R43GM105306
Amount: $239,875.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIGMS
Solicitation Number: PA12-088
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
United States
DUNS: 830912510
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (408) 616-7306
Business Contact
Phone: (650) 888-7160
Research Institution

DESCRIPTION (provided by applicant): Medikine will use SBIR funding to develop a new technology that will greatly accelerate the discovery of peptide agonists of cytokine receptors, and will make possible the re-engineering of these newly discovered agonists to exhibit novel and medically-valuable bioactivity profiles. This technology will enable the sorting of enormous libraries of stochastically-produced peptides to directly identify those with appropriate receptor- activating properties. This is an important advance beyond the current state-of-the-art in peptide agonist discovery methods that rely on screening for binding to a target receptor, followed by hit confirmation, peptide re-synthesis, and testing for agonist activity one compound at a time. Incontrast, Medikine proposes to develop a high throughput method of screening large collections of peptides for functional properties, not simply for binding. This will be accomplished by creating libraries of peptide producing bacteria engineered to express the peptides in a form suitable for direct testing for cytokine receptor activation in ultra-high-throughput formats. The resulting functional assays are designed to identify peptides with new cytokine-like properties useful for many therapeutic applications in diabetes, obesity, fibrosis, cancer, and immunotherapy. In Phase I studies, a suitable strain of peptide-producing bacteria will be constructed, and performance of the peptide in a cytokine receptor activation assay will be assessed. Achievement ofPhase I objectives will provide the groundwork for a Phase II SBIR program to develop a high-throughput, well-free technology to screen the activity of large peptide libraries; and to utilize this method for the discovery of peptides that faithfully mimic te activities of natural cytokines. Specific goals of Phase II will include development of protocols t screen large peptide collections for novel cytokine receptor agonists, and methods of selecting peptides that induce novel patterns of signal transduction activation leading to new and useful cytokine-like bioactivities. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Biopharmaceuticals based on natural cytokines comprise a huge and growing market. Blockbusters such as EPO, insulins, interferons, GCSF, and hGH are the most commercially successful members of the cytokine family, and there are dozens more currently-marketed or potentially useful for a growing number of important medical indications. Cytokines address substantial unmet medical needs, and have attained great commercial success despite a variety of shortcomings: serious side-effects, immunogenicity, short circulating half-life, poor chemical stability, and high cost of goods. Medikine's SBIR technology will provide a highly efficient and rapid method, based on direct detection of biological activity,to identify new peptide-based medicines that mimic or improve upon the medicinal properties, and avoid the deficiencies, of natural cytokines.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government